Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016 (2016), Article ID 1015390, 13 pages
http://dx.doi.org/10.1155/2016/1015390
Research Article

Soluble Receptor for Advanced Glycation End Product Ameliorates Chronic Intermittent Hypoxia Induced Renal Injury, Inflammation, and Apoptosis via P38/JNK Signaling Pathways

1Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Clinical Center for Sleep Breathing Disorder and Snoring, Zhongshan Hospital, Fudan University, Shanghai 200032, China
3Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
4Department of Respiratory Medicine, Affiliated Jiangyin Hospital of Southeast University, Jiangyin 214400, China
5Department of Respiratory Medicine, Ningbo Medical Center Lihuili Eastern Hospital, Taipei Medical University Ningbo Medical Center, Ningbo 315040, China

Received 18 April 2016; Revised 12 July 2016; Accepted 25 July 2016

Academic Editor: Hariom Yadav

Copyright © 2016 Xu Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. D. M. Nicholl, S. B. Ahmed, A. H. S. Loewen et al., “Clinical presentation of obstructive sleep apnea in patients with chronic kidney disease,” Journal of Clinical Sleep Medicine, vol. 8, no. 4, pp. 381–387, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. P. L. Kimmel, G. Miller, and W. B. Mendelson, “Sleep apnea syndrome in chronic renal disease,” The American Journal of Medicine, vol. 86, pp. 308–314, 1989. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Sim, S. A. Rasgon, D. A. Kujubu et al., “Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohor,” Chest, vol. 135, no. 3, pp. 710–716, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Hanly and S. B. Ahmed, “Sleep apnea and the kidney: is sleep apnea a risk factor for chronic kidney disease?” Chest, vol. 146, no. 4, pp. 1114–1122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Beecroft, A. Pierratos, and P. J. Hanly, “Clinical presentation of obstructive sleep apnea in patients with end-stage renal disease,” Journal of Clinical Sleep Medicine, vol. 5, no. 2, pp. 115–121, 2009. View at Google Scholar · View at Scopus
  6. A. A. Chiang, “Obstructive sleep apnea and chronic intermittent hypoxia: a review,” Chinese Journal of Physiology, vol. 49, no. 5, pp. 234–243, 2006. View at Google Scholar · View at Scopus
  7. D. Stern, S. D. Yan, S. F. Yan, and A. M. Schmidt, “Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings,” Advanced Drug Delivery Reviews, vol. 54, no. 12, pp. 1615–1625, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. K.-M. Wu, C.-C. Lin, C.-H. Chiu, and S.-F. Liaw, “Effect of treatment by nasal continuous positive airway pressure on serum high mobility group box-1 protein in obstructive sleep apnea,” Chest, vol. 137, no. 2, pp. 303–309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Duru, I. Hikmet Firat, N. Colak, Z. Giniş, T. Delibaşi, and S. Ardiç, “Serum S100B protein: a useful marker in obstructive sleep apnea syndrome,” Neurologia i Neurochirurgia Polska, vol. 46, no. 5, pp. 450–455, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. E. J. Lee, E. Y. Park, H. Mun et al., “Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation,” The FASEB Journal, vol. 29, no. 8, pp. 3506–3514, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. V. D'Agati and A. M. Schmidt, “RAGE and the pathogenesis of chronic kidney disease,” Nature Reviews Nephrology, vol. 6, no. 6, pp. 352–360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. Y.-S. Bao, S.-P. Na, P. Zhang et al., “Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease,” Journal of Clinical Immunology, vol. 32, no. 3, pp. 587–594, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Zhu, L. Xie, H.-S. Ding, Q. Gong, J. Yang, and L. Yang, “High mobility group box 1 and kidney diseases (Review),” International Journal of Molecular Medicine, vol. 31, no. 4, pp. 763–768, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses,” The Journal of Clinical Investigation, vol. 108, no. 7, pp. 949–955, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Bruchfeld, A. R. Qureshi, B. Lindholm et al., “High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD),” Molecular Medicine, vol. 14, no. 3-4, pp. 109–115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T.-B. Zhou, “Role of high mobility group box 1 and its signaling pathways in renal diseases,” Journal of Receptors and Signal Transduction, vol. 34, no. 5, pp. 348–350, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Leonardis, G. Basta, F. Mallamaci et al., “Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD),” Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, no. 9, pp. 748–755, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Y. Park, B. H. Kim, E. J. Lee et al., “Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease,” The Journal of Biological Chemistry, vol. 289, no. 13, pp. 9254–9262, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Li, Q. Gong, S. Zhong et al., “Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury,” Nephrology Dialysis Transplantation, vol. 26, no. 2, pp. 469–478, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Vazzana, F. Santilli, C. Cuccurullo, and G. Davì, “Soluble forms of RAGE in internal medicine,” Internal and Emergency Medicine, vol. 4, no. 5, pp. 389–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Kalousová, M. Hodková, M. Kazderová et al., “Soluble receptor for advanced glycation end products in patients with decreased renal function,” American Journal of Kidney Diseases, vol. 47, no. 3, pp. 406–411, 2006. View at Publisher · View at Google Scholar
  22. M. F. Angelo, A. Aguirre, R. X. A. Reyes et al., “The proinflammatory RAGE/NF-κB pathway is involved in neuronal damage and reactive gliosis in a model of sleep apnea by intermittent hypoxia,” PLoS ONE, vol. 9, no. 9, Article ID e107901, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Fu, L. Jiang, F. Zhu et al., “Chronic intermittent hypoxia leads to insulin resistance and impaired glucose tolerance through dysregulation of adipokines in non-obese rats,” Sleep and Breathing, vol. 19, no. 4, pp. 1467–1473, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. D. G. S. Farmer, M.-A. Ewart, K. M. Mair, and S. Kennedy, “Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hypoxia in the mouse,” Pulmonary Pharmacology and Therapeutics, vol. 29, no. 1, pp. 7–14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. C. F. Islam, R. T. Mathie, M. D. Dinneen, E. A. Kiely, A. M. Peters, and P. A. Grace, “Ischaemia-reperfusion injury in the rat kidney: the effect of preconditioning,” British Journal of Urology, vol. 79, no. 6, pp. 842–847, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Nakao, J. S. Neto, S. Kanno et al., “Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both,” American Journal of Transplantation, vol. 5, no. 2, pp. 282–291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Z. Bagci, Y. Vodovotz, T. R. Billiar, G. B. Ermentrout, and I. Bahar, “Bistability in apoptosis: roles of Bax, Bcl-2, and mitochondrial permeability transition pores,” Biophysical Journal, vol. 90, no. 5, pp. 1546–1559, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Bierhaus, P. M. Humpert, M. Morcos et al., “Understanding RAGE, the receptor for advanced glycation end products,” Journal of Molecular Medicine, vol. 83, no. 11, pp. 876–886, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Pichiule, J. C. Chavez, A. M. Schmidt, and S. J. Vannucci, “Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia,” The Journal of Biological Chemistry, vol. 282, no. 50, pp. 36330–36340, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Basta, G. Lazzerini, M. Massaro et al., “Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses,” Circulation, vol. 105, no. 7, pp. 816–822, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Faraco, S. Fossati, M. E. Bianchi et al., “High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo,” Journal of Neurochemistry, vol. 103, no. 2, pp. 590–603, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. G.-Y. Gwak, T. G. Moon, D. H. Lee, and B. C. Yoo, “Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway,” World Journal of Gastroenterology, vol. 18, no. 7, pp. 679–684, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. J.-B. Kim, S. C. Joon, Y.-M. Yu et al., “HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain,” The Journal of Neuroscience, vol. 26, no. 24, pp. 6413–6421, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Oyama, T. Hashiguchi, N. Taniguchi et al., “High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy,” Laboratory Investigation, vol. 90, no. 6, pp. 853–866, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. U. Andersson, H. Wang, K. Palmblad et al., “High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes,” The Journal of Experimental Medicine, vol. 192, no. 4, pp. 565–570, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Lau, S. Wang, W. Liu, A. Haig, Z.-X. Zhang, and A. M. Jevnikar, “Glycyrrhizic acid ameliorates HMGB1-mediated cell death and inflammation after renal ischemia reperfusion injury,” American Journal of Nephrology, vol. 40, no. 1, pp. 84–95, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Y. Jhun, S. H. Lee, H. Y. Kim et al., “HMGB1/RAGE induces IL-17 expression to exaggerate inflammation in peripheral blood cells of hepatitis B patients,” Journal of Translational Medicine, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. E. M. Akirav, P. Preston-Hurlburt, J. Garyu et al., “RAGE expression in human T cells: a link between environmental factors and adaptive immune responses,” PLoS ONE, vol. 7, no. 4, Article ID e34698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. C.-C. Lee, Y.-T. Lai, H.-T. Chang et al., “Inhibition of high-mobility group box 1 in lung reduced airway inflammation and remodeling in a mouse model of chronic asthma,” Biochemical Pharmacology, vol. 86, no. 7, pp. 940–949, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Villarreal, R. X. Aviles Reyes, M. F. Angelo, A. G. Reinesf, and A. J. Ramos, “S100B alters neuronal survival and dendrite extension via RAGE-mediated NF-κB signaling,” Journal of Neurochemistry, vol. 117, no. 2, pp. 321–332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Shi, A. Lian, and F. Zhang, “Nuclear factor-κB activation inhibitor attenuates ischemia reperfusion injury and inhibits Hmgb1 expression,” Inflammation Research, vol. 63, no. 11, pp. 919–925, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. T. M. Wendt, N. Tanji, J. Guo et al., “RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy,” American Journal of Pathology, vol. 162, no. 4, pp. 1123–1137, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Simm, G. Münch, F. Seif et al., “Advanced glycation endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1,” FEBS Letters, vol. 410, no. 2-3, pp. 481–484, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Adhikary, F. Chow, D. J. Nikolic-Paterson et al., “Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy,” Diabetologia, vol. 47, no. 7, pp. 1210–1222, 2004. View at Google Scholar · View at Scopus
  45. C.-H. Wu, C.-M. Huang, C.-H. Lin, Y.-S. Ho, C.-M. Chen, and H.-M. Lee, “Advanced glycosylation end products induce NF-κB dependent iNOS expression in RAW 264.7 cells,” Molecular and Cellular Endocrinology, vol. 194, no. 1-2, pp. 9–17, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. H. M. Lander, J. M. Tauras, J. S. Ogiste, O. Hori, R. A. Moss, and A. M. Schmidt, “Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress,” The Journal of Biological Chemistry, vol. 272, no. 28, pp. 17810–17814, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Taguchi, D. C. Blood, G. del Toro et al., “Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases,” Nature, vol. 405, no. 6784, pp. 354–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Y. Park, M. J. Seo, and J. H. Park, “Effects of specific genes activating RAGE on polycystic kidney disease,” American Journal of Nephrology, vol. 32, no. 2, pp. 169–178, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. R. G. Iannitti, A. Casagrande, A. De Luca et al., “Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 11, pp. 1338–1350, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. M. A. H. Bowman and A. M. Schmidt, “The next generation of RAGE modulators: implications for soluble RAGE therapies in vascular inflammation,” Journal of Molecular Medicine, vol. 91, no. 12, pp. 1329–1331, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Guo, X. Zeng, J. Song et al., “A soluble receptor for advanced glycation end-products inhibits hypoxia/reoxygenation-induced apoptosis in rat cardiomyocytes via the mitochondrial pathway,” International Journal of Molecular Sciences, vol. 13, no. 9, pp. 11923–11940, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Raucci, S. Cugusi, A. Antonelli et al., “A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10),” The FASEB Journal, vol. 22, no. 10, pp. 3716–3727, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Gong, L. Xiang, L. Yuan et al., “Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats,” PLoS ONE, vol. 9, no. 3, Article ID e89450, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Geroldi, C. Falcone, E. Emanuele et al., “Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension,” Journal of Hypertension, vol. 23, no. 9, pp. 1725–1729, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. K.-H. Chiang, P.-H. Huang, S.-S. Huang, T.-C. Wu, J.-W. Chen, and S.-J. Lin, “Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients,” Coronary Artery Disease, vol. 20, no. 4, pp. 267–273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Kalousová, M. Jáchymová, M. Oto et al., “Receptor for advanced glycation end products—soluble form and gene polymorphisms in chronic haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 22, no. 7, pp. 2020–2026, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Liliensiek, M. A. Weigand, A. Bierhaus et al., “Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response,” The Journal of Clinical Investigation, vol. 113, no. 11, pp. 1641–1650, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Renard, O. Chappey, M.-P. Wautier et al., “Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats,” Molecular Pharmacology, vol. 52, no. 1, pp. 54–62, 1997. View at Google Scholar · View at Scopus
  59. G. Daffu, C. H. del Pozo, K. M. O'Shea, R. Ananthakrishnan, R. Ramasamy, and A. M. Schmidt, “Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond,” International Journal of Molecular Sciences, vol. 14, no. 10, pp. 19891–19910, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. W. Jiang, C. W. Bell, and D. S. Pisetsky, “The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid,” The Journal of Immunology, vol. 178, no. 10, pp. 6495–6503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. M. J. Robinson, P. Tessier, R. Poulsom, and N. Hogg, “The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 5, pp. 3658–3665, 2002. View at Publisher · View at Google Scholar · View at Scopus